As widely acknowledged, 40–50% of all melanoma patients harbour an activating BRAF
mutation (mostly BRAF V600E). The identification of the RAS–RAF–MEK–ERK (MAP kinase) …

The majority of patients with advanced ovarian cancer progress after first‐line therapy and
require further treatment. Tumor biology, prior chemotherapy, responses to previous therapy, …

Endometrial cancer (EC) is the most frequent gynecological cancer. In patients with relapsed
and advanced disease, prognosis is still dismal and development of resistance is common. …

Background The efficacy of risk model scores to predict venous thromboembolism (VTE) in
ambulatory cancer patients is under investigation, aiming to stratify on an individual risk basis …

The proportion of patients with metastatic colorectal cancer (mCRC) receiving second or
further lines of treatment has not been widely studied. To shed light on this issue, we …

Advanced, recurrent and metastatic endometrial cancer (EC) has a dismal prognosis due to
poor response rates to conventional treatments. In the era of precision medicine, the …

Mucosal melanomas (MM) are rare tumors, being less than 2% of all diagnosed melanomas,
comprising a variegated group of malignancies arising from melanocytes in virtually all …

Neutrophil-to-lymphocyte ratio (NLR) and systemic inflammatory index (SII) are prognostic
factors in epithelial ovarian cancer (EOC). Their predictive value for platinum-sensitivity and …

The treatment approach to cervix cancer has remained unchanged for several decades and
new therapeutic strategies are now required to improve outcomes, as the prognosis is still …

The majority of patients with advanced ovarian germ cell cancer are treated by cisplatin-based
chemotherapy. Despite adequate first-line treatment, nearly one third of patients relapse …